Thymia is a London-based healthtech startup developing AI-powered gamified tools for objective mental health assessment and monitoring. Founded in 2020 by neuroscientist Dr. Emilia Molimpakis, theoretical physicist Dr. Stefano Goria, and healthcare growth specialist Gabrielle Powell, the company uses neuropsychology, linguistics, and machine learning to detect symptoms of depression, anxiety, and ADHD.

The platform presents patients with short video-game-based tasks that capture multimodal biomarkers including voice patterns (intonation, speech rate), facial microexpressions, upper body movement, and behavioral metrics (reaction times, error rates). Proprietary AI models analyze these data streams against a dataset of over 1.1 billion data points collected from nearly 6,000 individuals. The system reports up to 84% accuracy in detecting clinical depression and anxiety.

Thymia targets clinical settings (diagnosis support, treatment response monitoring, remote patient tracking between appointments) and corporate wellbeing programs (workforce mental wellness screening using speech-only analysis). The company collaborates with King's College London, UCL, and Oxford University, operates across four continents, and has raised approximately EUR 3.1 million. Thymia is pursuing medical device approval to scale its technology in clinical workflows.